Cramer is always on the hunt for a long-term theme that can generate returns, regardless of what happens in the world.» Read More
Ever notice the mania that follows each Wednesday’s report? Here’s how you capitalize on it.
The record run-up in oil prices over recent years is igniting fierce debate over the "peak oil" theory — that once the maximum rate of global production is reached, a steep decline ensues. Here we present two squarely opposed viewpoints on the issues from rivals who have been sparring for years.
With growing talk about peak oil — when the globe’s petroleum reserves begin an inexorable decline — exploration companies are increasingly turning high-tech to delay this eventuality. There's been stunning advances in the industry's ability to visualize what lies deep underground and to extract more of what's down there.
The future of this renewable energy source is bright, especially since it's expected to be cost-competitive within five years. And the US is well-positioned to benefit.
Exxon Mobil, British Petroleum, Royal Dutch Shell and Total are reportedly near a deal with the Iraqi Oil Ministry that will grant the oil giants "no-bid" contracts for access to the country’s oil fields. This will mark the first time these firms have had commercial access to Iraq since the U.S. invasion in 2003.
The seemingly endless surge in energy prices is lightening wallets at gas stations, but it's also a potential bonanza for investors.
The State Administration of Foreign Exchange, an arm of China's central bank, has agreed to invest more than $2.5 billion in the latest fund being set up by U.S. private equity firm TPG Capital, the Financial Times reported on Wednesday.
This much is clear: European nation states are focusing on different ways of securing energy supplies for the long-term through a mix of politics and innovation.
But for its renewables commitment BP really deserves due credit, as does its earnest engagement in shaping what they acknowledge is a ‘carbon-constrained world.’ That's a phrase this reporter first heard more than three years ago from Jim Rogers...
Petrobras, the Brazilian oil producer that’s rapidly emerging as one of the world’s top companies, is “finding very good results” at its newly discovered off-shore deposits, Chief Executive Jose Sergio Gabrielli de Azevedo told CNBC in an exclusive interview.
There is a notable omission, one that exposes a fundamental contradiction, not just in this well-meaning company, but in across the energy sector, struggling to adjust to a carbon-constrained world.
Syngenta, Monsanto and Bunge should be bought on any discount, Cramer says.
The world's biggest oil companies depend on Nordic American to lug their product across the globe. With the price per barrel at all-time highs, it's a good business to be in.
Muscular retail sales figures encouraged traders -- as the dollar slips again and crude oil continues to soar. How should investors read these ostensibly contradictory signs? Erik Ristuben of Russell Investment Group and Holly Isdale of Lehman Brothers offered their sector insights to CNBC.
Chevron, the second-largest U.S. oil company, said Friday its first-quarter earnings rose 10 percent as record oil prices outweighed weak profits from gasoline production.
Exxon Mobil posted disappointing first-quarter earnings, as record crude oil prices did not help the company as much as investors hoped.
What's wrong with this picture? Crude oil is on a tear, but ExxonMobil shares have barely budged in NINE months. Can tomorrow's earnings knock the oil giant out of its trading range?
Stocks closed mixed in thin trading Tuesday as the tide turned in technology's favor. Airline stocks rose as oil prices receded. Merck skidded after an FDA rejection.
Stocks pushed higher Tuesday despite concerns about interest rates ahead of the Federal Reserve's decision. Merck skidded after an FDA rejection. Airline stocks rose as oil prices receded.
Stocks declined Tuesday amid concerns about interest rates and a slide in consumer confidence. Merck dragged on the Dow industrials after the FDA rejected a key cholesterol drug.